SEC Form 4 · accession 0001578563-18-000012
Avalo Therapeutics, Inc. · AVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter Greenleaf
Officer — Chief Executive Officer · Director
Period of report
May 18, 2018
Accepted (ET)
May 21, 2018 · 7:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001534120
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 18, 2018 | P | 12,500 | $3.98 | A | 412,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $0.80 | holding | — | — | — | — | May 11, 2027 | Common Stock | 16,714 | 16,714 | D |
| Employee Stock Option (Right to Buy)F3 | $0.57 | holding | — | — | — | Jun 30, 2018 | Jun 29, 2027 | Common Stock | 8,357 | 8,357 | D |
| Employee Stock Option (Right to Buy)F4 | $4.24 | holding | — | — | — | — | Mar 27, 2028 | Common Stock | 500,000 | 500,000 | D |
| Employee Stock Option (Right to Buy)F5 | $4.24 | holding | — | — | — | — | Mar 27, 2028 | Common Stock | 500,000 | 500,000 | D |
Explanation of responses
- F1This transaction was executed in multiple trades ranging from $3.95 to $4.00. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder full information regarding the number of shares and prices at which the transactions were effected.
- F2The stock option will vest in three substantially equal annual installments on May 11, 2018, 2019 and 2020, subject to the Reporting Person's continued service on each such vesting date.
- F3The stock options will vest in full on June 30, 2018, subject to the grantees continued service on such vesting date.
- F4The stock option will vest 25% on the first anniversary of the date of grant and the remaining 75% of the shares subject to the stock option shall vest in equal monthly installments on each monthly anniversary date of the first vesting date over the following 48 months beginning on April 27, 2019, provided the Reporting Person is then an officer of the Issuer on each such vesting date.
- F5The stock option will vest in full upon the Issuer's common stock closing at or above $12.50 per share for three consecutive trading days, provided the Reporting Person is then an officer of the Issuer on each such vesting date.